Text Size
1258 studies found for:    cancer | bevacizumab

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab
22 Recruiting First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
23 Active, not recruiting Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: sorafenib tosylate;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Biological: bevacizumab
24 Active, not recruiting First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: paclitaxel;   Drug: carboplatin;   Other: placebo;   Biological: bevacizumab
25 Recruiting Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions: Drug: RAD001;   Drug: bevacizumab
26 Terminated Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Stage II Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: paclitaxel;   Biological: bevacizumab;   Drug: carboplatin;   Other: laboratory biomarker analysis
27 Completed Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: bevacizumab;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
28 Recruiting Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: sorafenib tosylate;   Biological: bevacizumab;   Drug: leucovorin calcium;   Drug: fluorouracil
29 Completed Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: bevacizumab;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis
30 Active, not recruiting Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   No Prior Chemotherapy
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
31 Active, not recruiting Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Conditions: Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Carcinoma of the Vulva
Intervention: Drug: Avastin
32 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: immunohistochemistry staining method;   Other: flow cytometry;   Other: laboratory biomarker analysis
33 Terminated Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
Conditions: Adenocarcinoma of the Colon;   Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage III Colon Cancer;   Stage III Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: capecitabine;   Biological: bevacizumab;   Drug: fluorouracil;   Other: laboratory biomarker analysis
34 Completed Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
35 Terminated Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
Conditions: Cervical Cancer;   Uterine Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
36 Suspended Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Serous Cancer;   Fallopian Tube Cancer
Intervention: Drug: bevacizumab (Avastin)
37 Completed Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis
38 Terminated A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Conditions: Breast Neoplasms;   Breast Tumors;   Breast Cancer;   Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 706 placebo;   Drug: Bevacizumab;   Drug: AMG 706
39 Terminated
Has Results 		Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: Bevacizumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thymoglobulin
40 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Distal Urethral Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Proximal Urethral Cancer;   Recurrent Bladder Cancer;   Recurrent Prostate Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Stage IV Bladder Cancer;   Stage IV Prostate Cancer;   Transitional Cell Carcinoma of the Bladder;   Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: placebo;   Biological: bevacizumab;   Other: laboratory biomarker analysis
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years